Added to YB: 2023-12-18
Pitch date: 2023-12-18
ROIV [bullish]
Roivant Sciences Ltd.
+149.95%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Market Cap
$19.4B
Pitch Price
$11.01
Price Target
15.00 (-45%)
Dividend
N/A
EV/EBITDA
-12.54
P/E
-23.09
EV/Sales
1.2K
Sector
Biotechnology
Category
special_situation
Show full summary:
Free optionality with upside
$ROIV: $7B cash ($8/sh) from $7.25B Roche deal + $3.5B stake in $IMVT ($12/sh) yet trades ~$10 ignoring other assets. May return $1-2B to holders. $5-10/sh more from LNP suit, Vtama & Brepocitinib. 50% upside to $15, $24+ if goes well. Mkt undervalues portfolio.
Read full article (2 min)